stockrowPerrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Revenue
- −5.24%
- EPS
- −494.6%
- Free cash flow
- +138.5%
- Total debt
- −9.62%
Quarter to September 2026, against a year earlier
Follow PRGO
Alert me
Perrigo Company plc (PRGO) Net income
Perrigo Company plc's net income for fiscal 2025 was −$1.4B, compared with −$171.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.8B. Over the past ten years it has ranged from −$4.0B (fiscal 2016) to $146.1M (fiscal 2019); the current reading is higher than 17% of that period. Perrigo Company plc ranks 84th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$1.4B | — |
| FY2024 | −$171.8M | — |
| FY2023 | −$12.7M | — |
| FY2022 | −$140.6M | — |
| FY2021 | −$68.9M | — |
| FY2020 | −$162.6M | — |
| FY2019 | $146.1M | 11.53% |
| FY2018 | $131.0M | 9.53% |
| FY2017 | $119.6M | — |
| FY2016 | −$4.0B | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$27.5M | — |
| Jun 2026 | $74.5M | — |
| Mar 2026 | −$398.6M | — |
| Dec 2025 | −$1.4B | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $967.7M |
| PBH Prestige Consumer Healthcare Inc. compare | $155.1M |
| ANIP ANI Pharmaceuticals, Inc. compare | $116.8M |
| XERS Xeris Biopharma Holdings, Inc. compare | −$6.5M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.0M |
| ALVO Alvotech compare | −$179.6M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$359.7M |
| TRLV Trulieve Cannabis Corp. compare | −$446.6M |
| PRGO Perrigo Company plc | −$1.8B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on PRGO
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement